<?xml version="1.0" encoding="UTF-8"?>
<ref id="B179">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Vannice</surname>
    <given-names>K. S.</given-names>
   </name>
   <name>
    <surname>Wilder-Smith</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Barrett</surname>
    <given-names>A. D. T.</given-names>
   </name>
   <name>
    <surname>Carrijo</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Cavaleri</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>de Silva</surname>
    <given-names>A.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2018</year>). 
  <article-title>Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.</article-title>
  <source>
   <italic>Vaccine</italic>
  </source>
  <volume>36</volume>
  <fpage>3411</fpage>â€“
  <lpage>3417</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2018.02.062</pub-id>
  <?supplied-pmid 29525283?>
  <pub-id pub-id-type="pmid">29525283</pub-id>
 </mixed-citation>
</ref>
